The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Healthcare Setting.

The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Healthcare Setting. Thyroid. 2020 Apr 03;: Authors: Chen T, Gilfix B, Rivera JA, Sadeghi N, Richardson K, Hier MP, Forest VI, Fishman D, Caglar D, Pusztaszeri M, Mitmaker EJ, Payne RJ Abstract Though the current gold standard for diagnosing thyroid nodule malignancy is ultrasound-guided fine-needle aspiration (USFNA) cytology, about 20-25% of cytological evaluations are considered indeterminate for malignancy. This limitation has led to the emergence of next-generation sequencing panels, e.g. ThyroSeq v3 (TSv3), which recognize highly-diagnostic genetic mutations of common thyroid carcinomas in FNA samples and classifies them as test-negative or test-positive, helping optimize treatment for indeterminate thyroid nodules (ITNs). Our goals were to evaluate the benign call rate (BCR) of TSv3 and assess its diagnostic performance and clinical utility while highlighting the points of consideration for a public Canadian institution. This is a single-center study conducted at the Royal Victoria Hospital (McGill University Health Centre) in Montreal, Canada, between January and February 2019. Patients were offered TSv3 following the McGill Algorithm for ITN workup, a novel protocol developed at our institution to select only diagnostic surgery candidates in order to minimize waste of public resources, considering the single-payer h...
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research